Browse studies

Find your next paid study

1,252 recruiting studies matching your filters

Investigator-Initiated Feasibility Study of a Novel Endoscopic Ultrasound Guided Microwave Ablation Device in Patients With Locally Advanced, Unresectable, or Metastatic Cancer

The goal of this study is to assess the overall success of energy delivery during treatment using the ultrasound guided microwave ablation device in patients w…

Pancreatic CancerLiver Cancer (Locally Advanced or Metastatic)Pancreatic Cancer Non-resectable+6 more

Estimated

~$10 – $7,500

Banner HealthNCT07817147

Phase 3

Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy

This phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian …

Advanced Ovarian CarcinomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid Tumor+22 more

Estimated

Observational

Collection of Uterine Lavage in High-Risk Patients as a Potential Biomarker for Ovarian Cancer Risk

This clinical trial develops a non-surgical approach using uterine lavage samples to screen for progression to ovarian cancer in high-risk patients carrying BR…

BRCA Hereditary Ovarian CarcinomaFallopian Tube High Grade Serous AdenocarcinomaOvarian High Grade Serous Adenocarcinoma+1 more

Estimated

~$10 – $6,250

University of WashingtonNCT07772869

Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix

This study collects information and data on patients with neuroendocrine cervical cancer. Information from this study may be used to better understand the corr…

Cervical Large Cell Neuroendocrine CarcinomaCervical Neuroendocrine CarcinomaCervical Small Cell Carcinoma+19 more

Estimated

~$10 – $750

Phase 3

A Randomised, Open-label, Phase III Study of Torvutatug Samrotecan With or Without Bevacizumab Versus Standard of Care as Second- or Third-Line Maintenance Treatment in Participants With Platinum-sensitive Relapsed Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (TREVI-OC-03)

The purpose of this study is to measure the efficacy and safety of torvutatug samrotecan (torvu-sam) with or without bevacizumab compared to standard of care (…

Platinum-sensitive Relapsed Epithelial Ovarian CancerPlatinum-sensitive Relapsed Fallopian Tube CancerPlatinum-sensitive Relapsed Primary Peritoneal Cancer

Estimated

~$10 – $7,500

AstraZenecaNCT07816666

Phase 1

A Phase 1/2 Study of BMS-986525 as Monotherapy and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer

The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Pumitamig in participants with Relapsed/Refracto…

Relapsed/Refractory Small Cell Lung Cancer

Estimated

~$10 – $7,500

Bristol-Myers SquibbNCT07325136

Phase 3

Evaluating Novel Therapies and ctDNA as a Marker in Curatively-Treated Gastrointestinal Cancers With Microscopic Residual Disease

This study is a non-randomized, open-label, multi-cohort, multi-site, pilot feasibility therapeutic trial. The study will enroll 20 patients across 4 cohorts (…

Colon AdenocarcinomaRectal AdenocarcinomaGastric Adenocarcinoma+4 more

Estimated

~$10 – $6,250

Georgetown UniversityNCT05482516

Phase 1

Iadademstat and Radiation Therapy With Atezolizumab in Extensive Stage Small-cell Lung Cancer (ES-SCLC) Patients With Persistent, Recurrent or Progressive Disease After First Line Systemic Therapy

This is a phase 1b dose escalation, open-label, non-randomized study of participants with residual, progressive or recurrent ES-SCLC who previously received pl…

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Estimated

~$10 – $6,250

Yale UniversityNCT07113691

Phase 2

A Randomized, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mortality worldwide, with poor survival prospects for metastatic disease. The…

Non-Small Cell Lung Cancer

A Phase I/II Open-label Study of DJI136, a DLL3-targeted CAR-T Therapy, in Adult Patients With ES-SCLC

This is a Phase I/II, open-label, non-randomized, multi-center study in patients with extensive-stage small cell lung cancer (ES-SCLC) to determine the recomme…

Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT07564401

Phase 2

A Phase 2 Pilot Study of Mirdametinib in Relapsed Refractory Chronic Lymphocytic Leukemia

This phase II trial tests the effect of mirdametinib in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has …

Recurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic Leukemia+1 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT07061951

Phase 2

A Phase 2 Randomized Study of Osimertinib Versus Osimertinib Plus Chemotherapy for Patients With Metastatic EGFR-Mutant Lung Cancers That Have Detectable EGFR-Mutant cfDNA in Plasma After Initiation of Osimertinib

This study will compare the effectiveness of osimertinib alone with the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with…

Metastatic Non-small Cell Lung Cancer

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT04410796